ibandronic acid has been researched along with Leukemia, Plasmacytic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alsina, M; Anderson, JL; Craig, F; Cruz, JC; Dallas, M; Roodman, GD; Yoneda, T | 1 |
1 other study(ies) available for ibandronic acid and Leukemia, Plasmacytic
| Article | Year |
|---|---|
Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma.
Topics: Animals; Bone Diseases; Bone Marrow Cells; Cell Division; Cell Survival; Diphosphonates; Disease Models, Animal; Humans; Hypercalcemia; Ibandronic Acid; Immunoglobulin G; Immunoglobulin kappa-Chains; Leukemia, Plasma Cell; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Transplantation; Osteoclasts; Osteolysis; Paraplegia; Tumor Cells, Cultured | 2001 |